|
1. Das SK, Ray K. Wilson's Disease: An Update. Nat Clin Pract Neurol. 2006; 2(9):482-93. 2. Ala A, Walker AP, Ashkan K, Dooley JS, Schilsky ML. Wilson's disease. Lancet. 2007 Feb; 369(9559):397-408. 3. Iorio R, D'Ambrosi M, Marcellini M, Barbera C, Maggiore G, Zancan L, et al. Serum transaminases in children with Wilson's disease. J Pediatr Gastroenterol Nutr. 2004 Oct;39(4):331-6. 4. Sternlieb I. Wilson’s Disease and pregnancy. Hepatology. 2000 Feb; 31(2): 531-32. 5. Albert C, Aynard B, Terbe V. D-Penicillamine induced rapidly progressive glomerulonephritis with membranous nephropathy in a patient with rheumatoid arthritis. Clin Exp Rheumatol. 1994; 12(Suppl 11): 108. 6. Kowalsky RJ, Falen SW. Radiopharmaceuticals in nuclear pharmacy and nuclear medicine. 1st. Washington D.C: Nature. 2004; pp: 710-50. 7. Reux B, Weber V, Galmier MJ, Borel M, Madesclaire M, Madelmont JC, et al. Synthesis and cytotoxic properties of new fluorodeoxyglucose-coupled chlorambucil derivatives. Bioorg Med Chem. 2008 May; 16(9):5004-20. doi:10.1016/j.bmc.2008.03.038 8. McCarthy TD, Karellas P, Henderson SA, Giannis M, O'Keefe DF, Heery G, et al. Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention. Mol Pharm. 2005 Jul-Aug;2(4):312-8. 9. Kim BY, Rutka JT, Chan WC. Nanomedicine. N Engl J Med. 2010 Dec; 363(25):2434-43. doi:10.1056/NEJMra0912273 10. Klajnert B, Bryszewska M. Dendrimers: properties and applications. Acta Biochim Pol. 2001;48(1):199-208. 11. Mashayekhi M, Amanlou M, Sadeghi K, Mosayebniya M, Ardestani M, Shafiee Mehravi B. Diethylentriaminepentaacetic Acid-deoxyglucoseamine (DTPA-DG): Novel Nanosized Anti-Wilson's Disease Cell Model. Am J Biomed Sci. 2013 Jan; 5(1):34-46. 12. Granqvist CG, Buhrman RA,Wyns J, Sievers AJ. Far-Infrared absorption in ultrarine al particles. Phys Rev Leet. 1976; 37(10): 625. http://dx.doi.org/10.1103/PhysRevLett.37.625 13. Cui Z, Lockman PR, Atwood CS, Hsu CH, Gupte A, Allen DD, et al. Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases. Eur J Pharm Biopharm. 2005 Feb;59(2):263-72. 14. Adelman HM, Winters PR, Mahan CS, Wallach PM. D-penicillamine-induced myasthenia gravis: diagnosis obscured by coexisting chronic obstructive pulmonary disease. Am J Med Sci. 1995 Apr;309(4):191-3. 15. Sperling RA, Gil PR, Zhang F, Zanella M, Parak WJ. Biological applications of gold nanoparticles. Chem Soc Rev. 2008; 37(9): 1896-908. doi:10.1039/B712170A 16. Jain K, Kesharwani P, Gupta U, Jain NK. Dendrimer toxicity: Let's meet the challenge. Int J Pharm. 2010 Jul; 394(1-2):122-42. doi:10.1016/j.ijpharm.2010.04.027 17. Kolhatkar RB, Kitchens KM, Swaan PW, Ghandehari H. Surface acetylation of polyamidoamine (PAMAM) dendrimers decreases cytotoxicity while maintaining membrane permeability. Bioconjug Chem. 2007 Nov-Dec;18(6):2054-60. 18. Namazi H, Adeli M. Novel linear-globular thermoreversble hydrogel ABA type copolymer from dendritic citric acide as the A blocks and poly (ethyleneglygol) as the B block. European Polymer Journal. 2003; 39(7): 1491-1500. doi:10.1016/S0014-3057(02)00385-3 19. D'Emanuele A, Attwood D. Dendrimer-drug interactions. Adv Drug Deliv Rev. 2005 Dec;57(15):2147-62.
|
